Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!

Learn More
Banner

Therapeutic Bispecific Antibody Development for Pancreatic Cancer

Therapeutic Bispecific Antibody Development for Pancreatic Cancer

Alfa Cytology is dedicated to providing comprehensive solutions for the creation of highly specific and potent bispecific antibodies, with a focus on optimizing antibody design, enhancing specificity, and improving efficacy, thus providing valuable tools for researchers involved in pancreatic cancer research.

Introduction to Therapeutic Bispecific Antibody

Therapeutic bispecific antibodies (bsAbs) are engineered proteins that possess the ability to simultaneously bind two distinct antigens, and this dual-binding ability gives them unique advantages over monoclonal antibodies, including higher selectivity and potency. This higher selectivity makes them ideal for therapeutics that require high specificity. The preparation of bispecific antibodies involves sophisticated techniques such as hybridoma technology, recombinant DNA technology, and chemical conjugation methods. These antibodies can be designed to bring immune cells into proximity with cancer cells, thereby facilitating targeted immune responses.

Fig. 1 Structure and target selection of bispecific antibodies.Fig. 1 Overview of structure and target selection of bispecific antibodies. (Sun Y, et al, 2023)

Classification of Bispecific Antibodies

According to structure, bispecific antibodies can be divided into two categories: IgG-Based bsAbs and Fragment-Based bsAbs.

  • IgG-based bsAbs. Structure mimics natural IgG antibodies, comprising two heavy chains and two light chains with an Fc region.
  • Fragment-based bsAbs. Composed of small antigen-binding fragments, often scFv (single-chain variable fragment) or sdAb (single-domain antibody) elements.

Fig. 2 Bispecific antibodies and their format.Fig. 2 Representative bispecific antibodies and their format. (Sun Y, et al, 2023)

Therapeutic Bispecific Antibody for Pancreatic Cancer

Bispecific Antibody Company Target Phase
AMG 424 Amgen CD3 and CLDN18.2 (Claudin 18.2) Phase I/II
REGN1979 Regeneron CD3 and CD20 Phase I/II
XmAb14045 Xencor CD3 and CD123 (Interleukin-3 receptor alpha chain) Phase I
ABBV181 BMS PD-1 and T-cell receptor (TCR) or tumor-associated antigen Phase I/II
DuoBody-CT040 Genmab CD3 and CTLA-4 Phase I

Our Services

Alfa Cytology's services involve a complete development pipeline from antigen design and immunization to antibody purification and characterization. We are committed to providing researchers with reliable and specific therapeutic bispecific antibody development services to aid in preclinical research and therapy development for pancreatic cancer.

Target Selection

Our bispecific antibody development services target key targets for pancreatic cancer therapy to improve specificity and efficacy. These targets include:

In therapeutic bsAbs development for pancreatic cancer, the selection of targets and target combinations is critical to effectively leverage the unique dual-binding capability of bsAbs. Here are some of the key targets and target combinations we offer:

  • EGFR and HER2
  • PD-L1 and CTLA-4
  • CD3 and Tumor-Associated Antigens (TAA) such as Mesothelin or MUC1
  • VEGF and Angiopoietin-2

Multiple Bispecific Antibody Format

Alfa Cytology can design a variety of bispecific antibody forms to meet different research and therapeutic needs, including:

  • IgG-like bispecific antibodies
  • Fragment-based bispecific antibodies
  • T-cell Engagers (TCEs)
  • BiTEs (Bispecific T-cell Engagers)
  • Trispecific antibodies
  • CrossMAb
  • Quadroma

Our Immune Response Screening Methods

ELISA

Quantify the antibody response against the target antigen in serum samples.

Western Blot

Assess the specificity and reactivity of the generated antibodies to the target protein in complex biological samples.

Flow Cytometry

Analyze the binding of antibodies to cell surface antigens, providing data on antibody specificity and binding affinity.

Immunohistochemistry

Examines the ability of antibodies to recognize target antigens in tissue sections, ensuring their applicability in histological studies.

Why Choose Us?

Tailored Solutions

Advanced Technology

Professional Expertise

Collaborative Approach

Alfa Cytology is a solution provider dedicated to helping our clients meet the key challenges encountered in the field of pancreatic cancer research. We offer a full suite of custom bispecific antibody services against a variety of antigens, and based on your application needs for these antibodies, our scientists will design custom immunization, screening, and purification strategies. Please contact us for more information.

Reference

  1. Sun Y, et al. Bispecific antibodies in cancer therapy: Target selection and regulatory requirements. Acta Pharmaceutica Sinica B. 2023, 13(9): 3583-3597.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.